Boehringer Ingelheim: Is Animal Health the sweet spot of the industry?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Boehringer Ingelheim: Is Animal Health the sweet spot of the industry?
Released on: June 09, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Dr Joachim Hasenmaier, corporate board divisions, Animal Health and Consumer Healthcare, discusses BI’s transformational swap with Sanofi, which has seen them acquire Sanofi’s Animal Health Division in exchange for Consumer Health.
  • Summary
  • Transcript
  • Participants
  • Company
Dr Joachim Hasenmaier, corporate board divisions, Animal Health and Consumer Healthcare, discusses BI’s transformational swap with Sanofi, which has seen them acquire Sanofi’s Animal Health Division in exchange for Consumer Health.
Dr Joachim Hasenmaier, corporate board divisions, Animal Health and Consumer Healthcare, discusses BI’s transformational swap with Sanofi, which has seen them acquire Sanofi’s Animal Health Division in exchange for Consumer Health.
Joachim Hasenmaier
Boehringer Ingelheim
Boehringer Ingelheim GmbH is a pharmaceutical company which concentrates on the development of human pharmaceuticals, biopharmaceuticals, chemicals, and animal health products. The Human Pharmaceuticals sector is the company's largest division, accounting for about 96% of sales. This includes prescription medicines and consumer healthcare products.